



## **TLC to Present at Upcoming Virtual Investor Conferences**

**SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan – September 9, 2021 – TLC** (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the Company's management team will be presenting at the following virtual investor conferences:

HC Wainwright & Co 23<sup>rd</sup> Annual Global Investment Conference

September 13-15, 2021

Presentation will be available on-demand during the conference

2021 Cantor Virtual Global Healthcare Conference

September 27-30, 2021

Presentation: 10:00am ET, Monday, September 27, 2021

The management team will also be participating in one-on-one meetings during the conference. The corporate presentation will be available on the TLC website at [www.tlcbio.com](http://www.tlcbio.com) in the Investors section, under News & Events.

### **About TLC**

TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD<sup>®</sup>). TLC's deep experience with liposome science allows a combination of onset speed and benefit duration, improving active drug concentrations while decreasing unwanted systemic exposures. TLC's BioSeizer<sup>®</sup> technology is designed to enable local sustained release of therapeutic agents at the site of disease or injury; its NanoX<sup>®</sup> active drug loading technology has been proven in two approved drugs and is designed to alter the systemic exposure of a drug, potentially reducing dosing frequency and enhancing distribution of liposome-encapsulated active agents to the desired site. These technologies are versatile in the choice of active pharmaceutical ingredients, and scalable with respect to manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics that target areas of unmet medical need in pain management, infectious diseases, ophthalmology, and oncology.

### **Contact**

Dawn Chi

Corporate Communications

[dawn@tlcbio.com](mailto:dawn@tlcbio.com)